AVEO Oncology

formerly AVEO PharmaAcquired

Advancing Cancer Treatment Innovation

AVEO Oncology is a biotech company in Boston, United States, founded in 2001. It has raised $204.0M across 5 rounds, most recently a $53.0M Series D in April 2007.

Employees
51–200
Founded
2001
Business Model
B2B
Total Funding
$204.0M
Last Round
$53.0M Series DApr 2007
Rounds
5
Acquisition Date
Oct 2022

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 5 funding rounds and 7 investors for this company. to use credits for reveals, or explore the API.

About

AVEO Oncology is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. Founded in 2001 and headquartered in Boston, Massachusetts, AVEO markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma. In January 2023, AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc., and continues to operate under the AVEO Oncology name.

Funding & Exit History

Data from Indexed.vcUpdated
AcquisitionNov 2022

12 more events

  • Acquisition20221 investor
  • Secondary Market2021
  • Secondary Market2021

Funding: Series A through Series D. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

  • Marketing & SEO ×3
  • Backend ×1
  • DevOps ×1
  • Other ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech
Corporate RoundTotal funding$2.8BJan 2020
Avenzo

Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...

San Diego, United States1–10Biotech
Series BTotal funding$832.0MSep 2025
Bicycle TherapeuticsIPO

Novel bicyclic peptides and drug conjugates for cancer

Cambridge, United States201–500Biotech
Private EquityTotal funding$607.0MJan 2024
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech
Private EquityTotal funding$3.0BJan 2004

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AVEO Oncology on Indexed.vc
<a href="https://indexed.vc/companies/aveo-oncology"><img src="https://indexed.vc/api/badge/company/aveo-oncology" alt="AVEO Oncology on Indexed.vc" width="260" height="76" /></a>